查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870891

克隆氏症治療市場：2025-2032年全球預測（依治療方法、給藥途徑、通路和最終用戶分類）

Crohn's Disease Therapeutics Market by Therapy Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，克隆氏症治療市場將成長至 209.2 億美元，複合年成長率為 5.76%。

關鍵市場統計數據
基準年 2024 133.6億美元
預計年份：2025年 141.3億美元
預測年份 2032 209.2億美元
複合年成長率 (%) 5.76%

全面介紹克隆氏症藥物市場：重點關注臨床促進因素、未滿足的需求和不斷發展的治療模式

克隆氏症仍然是一種複雜多樣的發炎性腸道疾病，對臨床醫生、支付方和生命科學創新者都構成了挑戰。過去十年，治療方法已從廣泛的免疫抑制療法轉向生物目標和小分子藥物策略，旨在調節特定的免疫路徑。因此，在治療決策中，平衡療效與以病人為中心的考量因素（例如長期安全性、免疫抗原性、給藥途徑和治療負擔）變得越來越重要。因此，相關人員必須應對這樣一種局面：臨床療效、便利性和安全性共同影響著藥物的接受度和病人的依從性。

變革性轉變重塑克隆氏症治療：新型作用機制、成功的臨床試驗、以病人為中心的服務模式與支付方趨勢

克隆氏症治療格局正在經歷變革，這主要得益於生物特異性的提升、口服小分子藥物的出現以及以患者為中心的醫療服務模式的日益普及。新型作用機制，例如更具選擇性的白細胞介素和整合素阻斷劑，正在改變人們對持久緩解和黏膜癒合的預期，而真實世界研究證據也進一步明確了這些藥物相對於傳統藥物的定位。同時，製劑和給藥方式的創新也拓展了治療選擇，提供了更方便的皮下和口服方案，從而減輕了患者的治療負擔。

評估美國2025年實施的累積關稅對治療藥物供應鏈、定價策略、臨床應用和創新獎勵的累積影響

美國將於2025年生效的累積關稅將為治療藥物供應鏈、商業性定價策略和廣泛進入機制創造新的營運環境。關稅導致的投入成本上漲，例如活性成分、生物製藥、管瓶和輔助耗材，可能會增加生產和分銷成本。為此，製造商可能會重新評估其海外供應集中度，加速本地生產投資，或調整籌資策略以降低關稅波動帶來的影響。

透過細分市場分析，深入了解治療層級、給藥途徑、分銷管道和最終用戶路徑對結果和商業策略的影響。

對克隆氏症藥物進行細分市場分析，揭示了治療層級、給藥途徑、分銷管道和最終用戶如何共同影響臨床和商業性結果。基於治療方法類別，市場可細分為生物製藥、免疫抑制劑和小分子藥物，生物製藥內部仍可進一步細分。具體類別包括整合素抑制劑（如維多珠單抗）、白細胞介素抑制劑（如利沙珠單抗和Ustekinumab單抗）以及TNF抑制劑（如Adalimumab、賽妥珠單抗和Infliximab）。免疫抑制劑通常為胺基甲基葉酸和硫嘌呤類藥物（包括Azathioprine和Mercaptopurine），而小分子藥物則以JAK抑制劑為主，主要是託法替尼和Upadacitinib，它們具有不同的監管和安全性特徵。

美洲、歐洲、中東和非洲以及亞太地區治療方案採納、法規結構、取得途徑和商業性動態的區域觀點

區域趨勢對於治療創新如何惠及患者以及如何在不同醫療體系中執行商業策略至關重要。美洲市場的特點是支付方結構分散、專科藥房網路強大，以及高度成熟的商業性模式，這些都有利於差異化的價值提案和基於績效的合約。同時，歐洲、中東和非洲地區（EMEA）的特點是監管和報銷環境複雜多樣，包括集中核准系統、國家層面的准入談判以及不同的衛生技術評估（HTA）實踐。這就要求制定適應性強的市場進入策略，並進行強力的本地證據收集工作。

主要企業層級深入檢驗克隆氏症治療領域的競爭定位、開發平臺、策略聯盟、生產規模和市場差異化策略。

公司層級針對克隆氏症治療的策略反映了產品組合多元化、定向研發投資和商業性合作的綜合策略。領先的生物製藥公司專注於差異化的作用機制，例如選擇性白細胞介素調節和腸道特異性整合素阻斷，同時投資於生命週期策略，例如適應症拓展、製劑替代和聯合治療。同時，中型市場和專業生物技術公司則透過生物標記驅動的研發和精準醫療方法，尋求利基市場定位，以滿足未被滿足需求的患者群體。

為指導克隆氏症藥物的臨床開發、商業性實施、病患取得和供應保障，提出實際的優先建議

克隆氏症病領域的領導企業應採取一系列優先行動，協調臨床開發、商業性執行和病患可及性這三大關鍵要素。首先，設計臨床計畫時，應將可靠的療效終點與可操作的真實世界數據結合，以滿足監管機構、付款者和臨床醫生的需求。這種雙重關注有助於將克隆氏症納入治療流程的優先順序。其次，透過地理多元化和合約彈性最佳化供應鏈，以減輕關稅和地緣政治動盪的影響，並確保慢性病患者治療的連續性。

一項綜合性的混合方法研究途徑，整合了專家訪談、系統性文獻回顧、供應鏈檢驗和資料三角測量。

本執行摘要的調查方法融合了多種定性和定量方法，以確保研究結果的可靠性和可重複性。主要研究包括對臨床意見領袖、支付方、專科藥劑師和商業領袖進行結構化訪談，以收集關於治療效果、推廣障礙和報銷趨勢的真實世界觀點。這些第一手研究結果輔以對同儕審查的臨床文獻、監管文件和指南更新的系統性回顧，以檢驗作用機制證據和安全性訊號。

結論整合了臨床、商業性和政策方面的啟示，供尋求推進治療方案和以病人為中心的護理路徑的利益相關人員參考。

總之，克隆氏症治療領域呈現出快速的治療創新、不斷演變的醫療服務模式和不斷變化的商業性格局，所有這些都要求產業和臨床相關人員具備策略靈活性。雖然生物製藥和口服小分子藥物特異性的提高正在拓展治療選擇，但它們的推廣應用將取決於其在現實世界中的療效、可控的安全性以及是否符合支付方的預期。同時，關稅政策的變化和供應鏈的脆弱性等外部因素也增加了營運風險，必須積極主動地加以管理。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 針對腸道菌叢的糞便微生物移植方案對克隆氏症臨床治療效果的影響
  • 口服小分子S1P受體調變器治療中重度克隆氏症的研發與臨床試驗進展
  • 高成本生物製藥的應用問題以及目前兒童克隆氏症症患者的保險覆蓋情況
  • 利用遠端數位健康平台進行個人化治療藥物監測在維持克隆氏症的新作用
  • 策略合作旨在推動克隆氏症雙標靶抗整合素和抗TNF聯合治療的研發

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章克隆氏症藥物市場（依治療類別分類）

  • 生物製藥
    • 整合素抑制劑
      • 維多珠單抗
    • 白細胞介素抑制劑
      • 利沙珠單抗
      • Ustekinumab
    • TNF抑制劑
      • Adalimumab
      • 賽妥珠單抗
      • Infliximab
  • 免疫抑制劑
    • 胺基甲基葉酸
    • 硫嘌呤
      • Azathioprine
      • Mercaptopurine
  • 低分子化合物
    • JAK抑制劑
      • 託法替尼
      • Upadacitinib

第9章克隆氏症藥物市場依給藥途徑分類

  • 靜脈注射
  • 口服
  • 皮下注射

第10章克隆氏症治療藥物市場（依通路分類）

  • 醫院藥房
  • 零售藥房
  • 專科診所

第11章克隆氏症治療藥物市場（以最終用戶分類）

  • 居家醫療環境
  • 醫院
  • 專科診所

第12章克隆氏症治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章克隆氏症治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國克隆氏症治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • Janssen Biotech, Inc.
    • Takeda Pharmaceutical Company Limited
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Merck & Co., Inc.
    • UCB SA
    • Celltrion, Inc.
    • Samsung Bioepis Co., Ltd.
    • Sandoz International GmbH
Product Code: MRR-1A1A064C0471

The Crohn's Disease Therapeutics Market is projected to grow by USD 20.92 billion at a CAGR of 5.76% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.36 billion
Estimated Year [2025] USD 14.13 billion
Forecast Year [2032] USD 20.92 billion
CAGR (%) 5.76%

Comprehensive introduction to Crohn's disease therapeutics landscape emphasizing clinical drivers, unmet needs, and evolving treatment paradigms

Crohn's disease remains a complex, heterogeneous inflammatory bowel condition that challenges clinicians, payers, and life science innovators. Over the past decade therapeutic approaches have shifted from broadly immunosuppressive regimens to targeted biologic and small molecule strategies designed to modulate specific immune pathways. As a result, treatment decision-making increasingly balances efficacy with long-term safety, immunogenicity, and patient-centered considerations such as route of administration and treatment burden. Consequently, stakeholders must navigate a landscape where clinical efficacy, convenience, and safety profiles jointly influence adoption and persistence.

In parallel, healthcare systems are adapting reimbursement models, specialty pharmacy operations, and specialty clinic capabilities to support more personalized treatment algorithms. Real-world evidence initiatives and longitudinal registries are expanding understanding of treatment durability and comparative effectiveness, which in turn shape clinical guidelines and payer coverage. Given these dynamics, strategic planning for product development, market entry, and access requires integrated insights that marry clinical science with commercial realities. This executive summary synthesizes those critical dimensions to help decision-makers identify opportunities and risks within the therapeutic continuum for Crohn's disease.

Transformative shifts reshaping Crohn's disease care including novel mechanisms of action, trial successes, patient-centric delivery models, and payer dynamics

The therapeutic landscape for Crohn's disease is undergoing transformational shifts driven by advances in biological specificity, the emergence of oral small molecules, and a growing emphasis on patient-centric care delivery. Novel mechanisms of action, including more selective interleukin and integrin blockade, are changing expectations for sustained remission and mucosal healing, while real-world evidence continues to refine positioning versus legacy agents. At the same time, innovation in formulation and administration is reducing treatment burden through more convenient subcutaneous dosing and oral options that expand settings of care.

Concurrently, payers and providers are recalibrating access pathways to manage the cost and clinical complexity of newer agents. Value-based contracting, outcomes-based agreements, and specialty pharmacy integration are gaining traction as tools to align cost with observed clinical benefit. Moreover, safety signals and lifecycle management considerations are influencing label expansions and post-marketing requirements, which drive clinicians to adopt risk-management strategies. Taken together, these shifts are producing a more stratified pathway for patients where treatment selection reflects not only disease biology but also delivery preferences, safety tolerance, and system-level incentives.

Assessing the cumulative impact of United States tariffs in 2025 on therapeutics supply chains, pricing strategies, clinical access, and innovation incentives

The introduction of cumulative United States tariffs in 2025 introduces a new operating context for therapeutic supply chains, commercial pricing strategies, and broader access dynamics. Tariff-driven increases in input costs for active pharmaceutical ingredients, biologic components, vials, and ancillary supplies can raise manufacturing and distribution expenditures. In response, manufacturers may reassess offshore supply concentration, accelerate regional manufacturing investments, or revise sourcing strategies to mitigate exposure to tariff volatility.

From a commercial perspective, incremental cost pressures can complicate negotiations with payers and integrated delivery networks, prompting stronger emphasis on total cost of care and outcomes-based arrangements. In the short term, providers and specialty pharmacies may experience inventory and fulfillment stress as suppliers reorganize logistics to accommodate tariff-related constraints. Over the medium term, policy-induced cost differentials can incentivize local production, contractual hedging, and increased vertical integration among suppliers to protect margin and secure supply reliability.

Finally, the tariff environment has implications for innovation incentives. Higher trade barriers can raise the effective cost of bringing complex biologics and high-value small molecules to market in the US, thereby influencing clinical development prioritization and go-to-market sequencing. As a result, strategic planning must account for scenarios that blend procurement complexity with payer sensitivity and evolving manufacturing footprints.

Segmentation insights into how therapy classes, administration routes, distribution channels, and end-user pathways influence outcomes and commercial strategy

A segmentation-aware view of Crohn's therapeutics reveals how therapeutic class, route of administration, distribution channel, and end user jointly shape clinical and commercial outcomes. Based on therapy class, the market divides into Biologics, Immunosuppressants, and Small Molecules, with further granularity within biologics to include Integrin Inhibitors such as vedolizumab, Interleukin Inhibitors including risankizumab and ustekinumab, and TNF Inhibitors such as adalimumab, certolizumab, and infliximab. Immunosuppressants are represented by agents like methotrexate and thiopurines, the latter subgroup including azathioprine and mercaptopurine, while small molecules center on JAK inhibitors with tofacitinib and upadacitinib illustrating divergent regulatory and safety profiles.

In addition, the route of administration-intravenous, oral, and subcutaneous-meaningfully influences clinical adoption, site-of-care economics, and patient preference. Distribution channels from hospital pharmacies to retail pharmacies and specialty clinics create distinct access and dispensing models that affect continuity of care and reimbursement complexity. Finally, end users span home care settings, hospitals, and specialty clinics, each with different capabilities for monitoring, adherence support, and infusion infrastructure. When considered together, these segmentation dimensions indicate that targeted strategies must be tailored to the interplay of mechanism of action, delivery modality, channel logistics, and care setting to optimize uptake and long-term persistence.

Regional perspectives on therapeutic adoption, regulatory frameworks, access pathways, and commercial dynamics across Americas, EMEA, and Asia-Pacific

Regional dynamics are pivotal to how therapeutic innovations reach patients and how commercial strategies are executed across disparate health systems. In the Americas, markets are characterized by fragmented payer landscapes, strong specialty pharmacy networks, and a high degree of commercial sophistication that favors differentiated value propositions and outcomes-based contracting. By contrast, Europe, Middle East & Africa presents a heterogenous regulatory and reimbursement environment in which centralized approvals coexist with country-level access negotiations and diverse health technology assessment practices, requiring adaptive market access strategies and robust local evidence generation.

In the Asia-Pacific region, evolving regulatory harmonization, growing local manufacturing capabilities, and rapid adoption of digital health tools are accelerating access to both biologics and small molecules. Pricing pressures and increasing emphasis on cost-effectiveness are driving tiered launch sequencing and selective commercialization models. Across all regions, stakeholders must align clinical trial design, real-world evidence programs, and supply chain resilience to regional policy nuances and payer expectations. Ultimately, region-specific regulatory frameworks, distribution infrastructures, and patient management norms will determine the pace and shape of adoption for new Crohn's therapeutics.

Key company-level insights examining competitive positioning, R&D pipelines, strategic partnerships, manufacturing scale, and go-to-market differentiation in Crohn's therapeutics

Company-level strategies in Crohn's disease therapeutics reflect a mix of portfolio diversification, targeted R&D investment, and commercial partnerships. Leading biopharmaceutical organizations are concentrating on differentiated mechanisms such as selective interleukin modulation and gut-specific integrin blockade while investing in lifecycle strategies that include label expansions, formulation alternatives, and combination approaches. At the same time, mid-sized firms and specialized biotech companies are pursuing niche positioning through biomarker-driven development and precision medicine approaches to capture segments of the patient population with unmet needs.

Manufacturing scale and supply chain agility are increasingly central to competitive advantage, prompting strategic partnerships, contract manufacturing diversification, and regional footprint expansion. Commercial differentiation hinges on integrated services; companies that complement drug efficacy with patient support programs, hub services for specialty distribution, and digital adherence tools are better positioned to maintain persistence and reduce overall cost of care. In this evolving competitive landscape, partnerships and licensing deals can accelerate market entry and broaden clinical utility, while targeted M&A activity supports vertical integration where it bolsters supply security or accelerates access to proprietary technologies.

Practical and prioritized recommendations guiding clinical development, commercial execution, patient access, and supply resilience for Crohn's therapeutics

Leaders in the Crohn's therapeutics space should adopt a set of prioritized actions that align clinical development with commercial execution and patient access imperatives. First, design clinical programs that generate both robust efficacy endpoints and pragmatic real-world measures to satisfy regulators, payers, and clinicians; this dual focus improves the case for preferred placement in treatment algorithms. Second, optimize supply chains through geographic diversification and contractual resilience to reduce exposure to tariff-driven or geopolitical disruptions and to ensure continuity of care for patients on chronic therapy.

Third, develop comprehensive access strategies that combine value-based contracting with specialty pharmacy integration and digital patient support to maximize adherence and persistence. Fourth, tailor launch sequencing by channel and setting of care-recognizing that intravenous, subcutaneous, and oral modalities demand distinct operational approaches and reimbursement negotiations. Finally, invest selectively in companion diagnostics and biomarker research to support targeted use cases and to clear pathways for premium positioning where clinical differentiation is demonstrable. By prioritizing these actions, organizations can translate clinical promise into sustainable commercial performance while safeguarding patient access.

Comprehensive mixed-method research approach integrating expert interviews, systematic literature review, supply chain validation, and data triangulation

The research methodology underpinning this executive summary integrates multiple qualitative and quantitative approaches to ensure robust, replicable insights. Primary research included structured interviews with clinical thought leaders, payers, specialty pharmacists, and commercial leaders to capture frontline perspectives on therapeutic performance, adoption barriers, and reimbursement dynamics. These firsthand inputs were complemented by systematic review of peer-reviewed clinical literature, regulatory documentation, and guideline updates to validate mechanistic rationale and safety signals.

To strengthen reliability, the analysis incorporated supply chain validation through vendor mapping and distributor interviews, as well as triangulation across data sources to reconcile discrepancies and surface consistent patterns. Scenario analysis was used to stress-test strategic assumptions-particularly around tariff impacts, route-of-care shifts, and payer contracting innovations-so that recommendations reflect plausible operational contingencies. Finally, editorial synthesis prioritized clarity and actionable relevance for decision-makers, with transparent note of limitations where primary evidence is still evolving, thereby enabling informed use of the intelligence in strategic planning.

Conclusion synthesizing clinical, commercial, and policy implications for stakeholders aiming to advance therapeutic options and patient-centric care pathways

In conclusion, the Crohn's disease therapeutics landscape is characterized by rapid therapeutic innovation, evolving care delivery models, and shifting commercial dynamics that together demand strategic agility from industry and clinical stakeholders. Advances in biologic specificity and oral small molecules are expanding treatment options, but adoption will pivot on demonstrable real-world benefits, manageable safety profiles, and alignment with payer expectations. At the same time, external factors such as tariff policy changes and supply chain fragility add layers of operational risk that must be proactively managed.

Therefore, stakeholders should pursue an integrated approach that links clinical differentiation with pragmatic access strategies, resilient manufacturing and distribution, and evidence generation tailored for local health system needs. When executed thoughtfully, such an approach can accelerate appropriate patient access, support sustainable commercial returns, and foster innovation that meaningfully improves long-term patient outcomes. These synthesized implications provide a strategic foundation for teams seeking to navigate near-term disruptions while positioning for enduring success in Crohn's therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of gut microbiome-targeted fecal microbiota transplant pipelines on Crohn's disease management outcomes in clinical practice
  • 5.2. Development and clinical trial progress of oral small-molecule S1P receptor modulators for moderate to severe Crohn's disease
  • 5.3. Adoption challenges and payer coverage landscape for high-cost biologic therapies in pediatric Crohn's disease populations
  • 5.4. Emerging role of personalized therapeutic drug monitoring using remote digital health platforms for Crohn's disease remission maintenance
  • 5.5. Strategic partnerships driving development of dual targeting anti-integrin and anti-TNF combination therapies in Crohn's disease

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Crohn's Disease Therapeutics Market, by Therapy Class

  • 8.1. Biologics
    • 8.1.1. Integrin Inhibitors
      • 8.1.1.1. Vedolizumab
    • 8.1.2. Interleukin Inhibitors
      • 8.1.2.1. Risankizumab
      • 8.1.2.2. Ustekinumab
    • 8.1.3. TNF Inhibitors
      • 8.1.3.1. Adalimumab
      • 8.1.3.2. Certolizumab
      • 8.1.3.3. Infliximab
  • 8.2. Immunosuppressants
    • 8.2.1. Methotrexate
    • 8.2.2. Thiopurines
      • 8.2.2.1. Azathioprine
      • 8.2.2.2. Mercaptopurine
  • 8.3. Small Molecules
    • 8.3.1. JAK Inhibitors
      • 8.3.1.1. Tofacitinib
      • 8.3.1.2. Upadacitinib

9. Crohn's Disease Therapeutics Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Crohn's Disease Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Retail Pharmacies
  • 10.3. Specialty Clinics

11. Crohn's Disease Therapeutics Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Crohn's Disease Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Crohn's Disease Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Crohn's Disease Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AbbVie Inc.
    • 15.3.2. Janssen Biotech, Inc.
    • 15.3.3. Takeda Pharmaceutical Company Limited
    • 15.3.4. F. Hoffmann-La Roche Ltd
    • 15.3.5. Pfizer Inc.
    • 15.3.6. Merck & Co., Inc.
    • 15.3.7. UCB S.A.
    • 15.3.8. Celltrion, Inc.
    • 15.3.9. Samsung Bioepis Co., Ltd.
    • 15.3.10. Sandoz International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CROHN'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CROHN'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CROHN'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPE